Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)

Mette Norman Erichsen; Tri Hien Viet Huynh; Bjarke Abrahamsen; Jesper Frank Bastlund; Christoffer Bundgaard; Olja Monrad; Anders Bekker-Jensen; Christina Wøhlk Nielsen; Karla Andrea Frydenvang; Anders Asbjørn Jensen; Lennart Bunch

doi:10.1021/jm1009154

Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)

Mette Norman Erichsen, Tri Hien Viet Huynh, Bjarke Abrahamsen, Jesper Frank Bastlund, Christoffer Bundgaard, Olja Monrad, Anders Bekker-Jensen, Christina Wøhlk Nielsen, Karla Andrea Frydenvang, Anders Asbjørn Jensen, Lennart Bunch

85 Citationer (Scopus)

Abstract

The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous system, where they are responsible for the reuptake of the excitatory neurotransmitter (S)-glutamate (Glu).(1)Recently, we have reported the discovery of the first subtype selective EAAT1 inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H- chromene-3-carbonitrile (UCPH-101) (1b) and presented an introductory structure-activity relationship (SAR) study.(2)Here, we present a detailed SAR by the design, synthesis, and pharmacological evaluation of analogues 1g-1t. By comparison of potencies of 1b, 1h, and 1i versus 1j, it is evident that potency is largely influenced by the chemical nature of the R¹ substituent. The study also demonstrates that any chemical change of the functional groups or a change to the parental scaffold results in the complete loss of inhibitory activity of the compounds at EAAT1. Finally, a bioavailability study of UCPH-101 determined the half-life to be 30 min in serum (rats) but also that it was not able to penetrate the blood-brain barrier to any significant degree.

Originalsprog	Engelsk
Tidsskrift	Journal of Medicinal Chemistry
Vol/bind	53
Udgave nummer	19
Sider (fra-til)	7180–7191
ISSN	0022-2623
DOI	https://doi.org/10.1021/jm1009154
Status	Udgivet - 14 okt. 2010

Emneord

Det tidligere Farmaceutiske Fakultet

Adgang til dokumentet

10.1021/jm1009154

Fingeraftryk

Dyk ned i forskningsemnerne om 'Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Erichsen, M. N., Huynh, T. H. V., Abrahamsen, B., Bastlund, J. F., Bundgaard, C., Monrad, O., Bekker-Jensen, A., Nielsen, C. W., Frydenvang, K. A., Jensen, A. A., & Bunch, L. (2010). Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101). Journal of Medicinal Chemistry, 53(19), 7180–7191. https://doi.org/10.1021/jm1009154

Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1 : 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101). / Erichsen, Mette Norman; Huynh, Tri Hien Viet; Abrahamsen, Bjarke et al.

I: Journal of Medicinal Chemistry, Bind 53, Nr. 19, 14.10.2010, s. 7180–7191.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Erichsen, MN, Huynh, THV, Abrahamsen, B, Bastlund, JF, Bundgaard, C, Monrad, O, Bekker-Jensen, A, Nielsen, CW, Frydenvang, KA , Jensen, AA & Bunch, L 2010, 'Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)', Journal of Medicinal Chemistry, bind 53, nr. 19, s. 7180–7191. https://doi.org/10.1021/jm1009154

Erichsen MN, Huynh THV, Abrahamsen B, Bastlund JF, Bundgaard C, Monrad O et al. Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101). Journal of Medicinal Chemistry. 2010 okt. 14;53(19):7180–7191. doi: 10.1021/jm1009154

Erichsen, Mette Norman ; Huynh, Tri Hien Viet ; Abrahamsen, Bjarke et al. / Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1 : 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101). I: Journal of Medicinal Chemistry. 2010 ; Bind 53, Nr. 19. s. 7180–7191.

@article{96e7f264c1604dec809fd3392d8ae406,

title = "Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1: 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)",

abstract = "The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous system, where they are responsible for the reuptake of the excitatory neurotransmitter (S)-glutamate (Glu).(1)Recently, we have reported the discovery of the first subtype selective EAAT1 inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H- chromene-3-carbonitrile (UCPH-101) (1b) and presented an introductory structure-activity relationship (SAR) study.(2)Here, we present a detailed SAR by the design, synthesis, and pharmacological evaluation of analogues 1g-1t. By comparison of potencies of 1b, 1h, and 1i versus 1j, it is evident that potency is largely influenced by the chemical nature of the R1 substituent. The study also demonstrates that any chemical change of the functional groups or a change to the parental scaffold results in the complete loss of inhibitory activity of the compounds at EAAT1. Finally, a bioavailability study of UCPH-101 determined the half-life to be 30 min in serum (rats) but also that it was not able to penetrate the blood-brain barrier to any significant degree.",

keywords = "Former Faculty of Pharmaceutical Sciences",

author = "Erichsen, {Mette Norman} and Huynh, {Tri Hien Viet} and Bjarke Abrahamsen and Bastlund, {Jesper Frank} and Christoffer Bundgaard and Olja Monrad and Anders Bekker-Jensen and Nielsen, {Christina W{\o}hlk} and Frydenvang, {Karla Andrea} and Jensen, {Anders Asbj{\o}rn} and Lennart Bunch",

year = "2010",

month = oct,

day = "14",

doi = "10.1021/jm1009154",

language = "English",

volume = "53",

pages = "7180–7191",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "19",

}

TY - JOUR

T1 - Structure-activity relationship study of first selective inhibitor of excitatory amino acid transporter subtype 1

T2 - 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101)

AU - Erichsen, Mette Norman

AU - Huynh, Tri Hien Viet

AU - Abrahamsen, Bjarke

AU - Bastlund, Jesper Frank

AU - Bundgaard, Christoffer

AU - Monrad, Olja

AU - Bekker-Jensen, Anders

AU - Nielsen, Christina Wøhlk

AU - Frydenvang, Karla Andrea

AU - Jensen, Anders Asbjørn

AU - Bunch, Lennart

PY - 2010/10/14

Y1 - 2010/10/14

N2 - The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous system, where they are responsible for the reuptake of the excitatory neurotransmitter (S)-glutamate (Glu).(1)Recently, we have reported the discovery of the first subtype selective EAAT1 inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H- chromene-3-carbonitrile (UCPH-101) (1b) and presented an introductory structure-activity relationship (SAR) study.(2)Here, we present a detailed SAR by the design, synthesis, and pharmacological evaluation of analogues 1g-1t. By comparison of potencies of 1b, 1h, and 1i versus 1j, it is evident that potency is largely influenced by the chemical nature of the R1 substituent. The study also demonstrates that any chemical change of the functional groups or a change to the parental scaffold results in the complete loss of inhibitory activity of the compounds at EAAT1. Finally, a bioavailability study of UCPH-101 determined the half-life to be 30 min in serum (rats) but also that it was not able to penetrate the blood-brain barrier to any significant degree.

AB - The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous system, where they are responsible for the reuptake of the excitatory neurotransmitter (S)-glutamate (Glu).(1)Recently, we have reported the discovery of the first subtype selective EAAT1 inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H- chromene-3-carbonitrile (UCPH-101) (1b) and presented an introductory structure-activity relationship (SAR) study.(2)Here, we present a detailed SAR by the design, synthesis, and pharmacological evaluation of analogues 1g-1t. By comparison of potencies of 1b, 1h, and 1i versus 1j, it is evident that potency is largely influenced by the chemical nature of the R1 substituent. The study also demonstrates that any chemical change of the functional groups or a change to the parental scaffold results in the complete loss of inhibitory activity of the compounds at EAAT1. Finally, a bioavailability study of UCPH-101 determined the half-life to be 30 min in serum (rats) but also that it was not able to penetrate the blood-brain barrier to any significant degree.

KW - Former Faculty of Pharmaceutical Sciences

U2 - 10.1021/jm1009154

DO - 10.1021/jm1009154

M3 - Journal article

C2 - 20857912

SN - 0022-2623

VL - 53

SP - 7180

EP - 7191

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 19

ER -